Phenazone as a marker of liver-metabolic function in patients with acute leukemia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 37, Issue 5, 1999, Pages 234-237

  Wiela Hojenska, A ^a   Orzechowska Juzwenko, K ^a   Usnarska Zubkiewicz, L ^a   Kotlarek Haus, S ^a   Hurkacz, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute myeloblastic leukemia; Anticancer drugs; Liver metabolic efficiency; Phenazone kinetics

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; LIVER ENZYME; MICROSOME ENZYME; PHENAZONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG OXIDATION; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTIPYRINE; BIOLOGICAL MARKERS; BIOTRANSFORMATION; EPIRUBICIN; FEMALE; HALF-LIFE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LIVER; MALE; MICROSOMES, LIVER;

EID: 0032964859     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ambre J, Graeff D, Bures F, Haupt D, Deason K 1977 Antipyrine metabolism and bronchogenic carcinoma. J Med 8: 57-69
2. Brodie BB, Axelrod J, Soberman R, Levy BB 1949 The estimation of antipyrine in biological materials. J Biol Chem 179: 25-29
3. Caraco Y. Zylber-Katz E, Berny EM, Levy M 1995 Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Eur J Clin Pharmacol 47: 525-530
4. Engel G, Hofman U, Heidemann H, Cosme J, Eichelbaum M 1996 Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalysing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59: 613-623
5. Evans DAP 1993 Genetic factors in drug therapy. Clinical and molecular pharmacogenetics. University Press, Cambridge
6. Fabre D, Bressolle F, Goméni R, Bouvet O, Dubois A, Raffanel C, Gris JC, Galtier M 1993 Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone antipyrine-pharmacokinetic parameters. Clin Pharmacokinet 24: 333-343
7. Hartleb M 1991 Drugs and the liver part II. The role of the antipyrine test in drug metabolism studies. Biopharm Drug Dis 12: 559-570
8. Higuchi T, Nakamura T, Uchino H 1980a Antipyrine metabolism in cancer patients. Cancer 45: 541-544
9. Higuchi T, Nakamura T, Uchino H 1980b Microsomal enzymes in patients with acute leukemia as determined by plasma half-life of antipyrine. Cancer Chemother Pharmacol 5: 55-59
10. Kellermann G, Jett JR, Luyten-Kellermann M, Moses HL, Fontatna RS 1980 Variation of microsomal mixed function oxidase and human lung cancer. Cancer 45: 1438-1442
11. Kivistö KT, Kroemer HK, Eichelbaum M 1995 The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40: 523-530
12. Ludovici M, Dolara P, Constantini A, Barbagli G, Calzolai A, Stomaci N 1983 Impairment of antipyrine metabolism in urinary tract cancer. Tumori 69: 221-222
13. Orzechowska-Juzwenko K, Wiela A, Cieslinska A, Roszkowska E 1987 Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. Cancer 59: 1607-1610
14. Radzikowska E, Gazdzik W, Rowinska-Zakrzewska E 1993 Antipyrine metabolism in lung cancer patients. Pneumonol Alergol Pol 61: 496-502
15. Sjöqvist F, Borga O, Dahl ML, Orme MLE 1997 Fundamentals of Clinical Pharmacology. In: Speight TM, Holford NHG (ed) Avery's Drug Treatment. Adis International, Auckland Chester, Frankfurt, pp 1-73
16. Sotaniemi EA, Pelkonen RD, Mokka RE, Huttunen R, Viljakainen E 1977 Impairment of drug metabolism in patients with liver cancer. Eur J Clin Invest 7: 269-274
17. Spatzenegger M, Jaeger W 1995 Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27: 397-417
18. Teunissen MWE, Willemse PHB, Sleijfer DT, Sluiter WJ, Breimer DD 1984 Antipyrine metabolism in patients with disseminated testicular cancer and the influence of cytostatic treatment. Cancer Chemother Pharmacol 13: 181-185
19. Wiela A, Orzechowska-Juzwenko K, Kotlarek-Haus S, Plamieniak B, Wolowiec D 1988 Phenazone pharmacokinetics as an index of hepatic metabolic efficiency. Int J Clin Pharm Ther Toxicol 26: 562-565
20. Wissel PS, Sordillo P, Magil GB 1989 The influence of antineoplastic chemotherapy on antipyrine metabolism in man. J Clin Pharmacol 29: 267-269
21. Woolley PV 1983 Hepatic and pancreatic damage produced by cytotoxic drugs. Cancer Treat Rev 10: 117-137